Futura Medical shares rise on ED licensing deal with Haleon
Futura Medical
34.85p
16:34 29/04/24
-1.69%
-0.60p
Shares in Futura Medical gained on Monday after the company said it signed a licensing deal with consumer heath care giant Haleon for the rights to exclusively commercialise its topical, gel-based erectile dysfunction treatment MED3000 in the USA.
FTSE 100
8,147.03
16:54 29/04/24
n/a
n/a
FTSE 350
4,481.53
16:44 29/04/24
n/a
n/a
FTSE AIM All-Share
763.33
16:59 29/04/24
n/a
n/a
FTSE All-Share
4,435.18
16:59 29/04/24
n/a
n/a
Haleon
331.30p
17:05 29/04/24
-0.93%
-3.10p
Pharmaceuticals & Biotechnology
22,868.13
16:44 29/04/24
0.42%
94.87
Futura will receive an initial upfront payment of $4m, royalty payments on all sales of MED3000 by Haleon and potential commercial and performance-driven sales milestone payments totalling between $5m and $45m payable over the course of several years